Skip to main content
Premium Trial:

Request an Annual Quote

BioFire Diagnostics to Use $25M Financing to Expand FilmArray Panels


BioFire Diagnostics said this week that it has completed a $25 million financing with Athyrium Opportunities Fund.

BioFire will use the proceeds to accelerate commercialization of its FilmArray diagnostic platform and develop diagnostic test panels beyond its FilmArray Respiratory Panel, which has obtained both a CE Mark and US Food and Drug Administration approval.

FilmArray integrates sample preparation, amplification, detection, and analysis, and is designed to provide results in about an hour with about two minutes of hands-on time, according to the company. The instrument performs PCR to initially amplify nucleic acids from target pathogens, and uses melt curve analysis for multiplexed detection.

The FilmArray Respiratory Panel simultaneously tests 17 viral targets and three bacterial targets. BioFire is also developing a blood culture ID panel, a gastrointestinal pathogen panel, and a meningitis panel for the system. The company initiated clinical trials for the blood culture ID panel in July (PCR Insider, 7/19/2012).

Last week BioFire announced that it changed its name from Idaho Technology to more accurately reflect its business strategy (PCR Insider, 8/30/2012).

BioFire CEO Kirk Ririe said in a statement this week that the Athyrium investment "strengthens our already solid capital position and the company's ability to further penetrate the molecular diagnostics market."

Richard Pines, a principal of Athyrium, said in a statement that his company believes that BioFire "is poised for significant future growth as hospitals continue to decentralize their molecular diagnostic workflows and increasingly demand access to multiplex systems that can handle their testing throughput."

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.